The response to pegylated interferon alpha 2a in haemodialysis patients with hepatitis C virus infection

Infection

Volumn 36, Issue 4, 2008, Pages 341-344

  Akhan, S C ^a   Kalender, B ^a   Ruzgar, M ^a  

^a KOCAELI UNIVERSITY   (Turkey)

Author keywords

[No Author keywords available]

Indexed keywords

PEGINTERFERON ALPHA2A; RIBAVIRIN; VIRUS RNA;

ADULT; ANEMIA; ANOREXIA; ARTICLE; COMBINATION CHEMOTHERAPY; CONTROLLED STUDY; DRUG EFFICACY; DRUG TOLERABILITY; FEMALE; FLU LIKE SYNDROME; FOLLOW UP; HEMODIALYSIS; HEMOGLOBIN BLOOD LEVEL; HEPATITIS C; HOSPITAL ADMISSION; HUMAN; HUMAN TISSUE; LEUKOPENIA; LIVER BIOPSY; MAJOR CLINICAL STUDY; MALE; MYALGIA; SIDE EFFECT; THROMBOCYTOPENIA; TREATMENT RESPONSE;

ADULT; ANTIVIRAL AGENTS; DRUG THERAPY, COMBINATION; FEMALE; GENOTYPE; HEPACIVIRUS; HEPATITIS C, CHRONIC; HUMANS; INTERFERON ALFA-2A; MALE; MIDDLE AGED; PLATELET COUNT; POLYETHYLENE GLYCOLS; RENAL DIALYSIS; RETROSPECTIVE STUDIES; RIBAVIRIN; RNA, VIRAL; TREATMENT OUTCOME;

EID: 50649109628     PISSN: 03008126     EISSN: None     Source Type: Journal    
DOI: 10.1007/s15010-008-7134-z     Document Type: Article

References (17)

1. Kokoglu OF, Ucmak H, Hosoglu S, Cetikaya A, Kantarceken B, Buyukbese MA, Isik IO: Efficacy and tolerability of pegylated-interferon alpha-2a in hemodialysis patients with chronic hepatitis C. J Gastroenterol Hepatol 2006; 39: 575-580.
2. Strader DB, Wright T, Thomas DL, Seeff LBAmerican Association for the study of liver diseases Diagnosis, management, and treatment of hepatitis C. Hepatol 2004; 39: 1147-1171.
3. Chayama K: Genotyping hepatitis C virus by type specific primers for PCR based on NS5 region. Humana Press, Totowa 1998.
4. Covic A, Maftei ID, Mardare NG, Ionita-Radu F, Totolici C, Tuta L, Golea O, Covic M, Volovat C, Gusbeth-Tatomir P, Mircescu G: Analysis of safety and efficacy of pegylated-interferon alpha-2a in hepatitis C virus positive hemodialysis patients: results from a large, multicenter audit. J Nephrol 2006; 19: 794-801.
5. Manns MP, Wedemeyer H, Cornberg M: Treating viral hepatitis C: efficacy, side effects, and complications Gut 2006; 55 (9): 1350-1359.
6. Akhan SC, Yulugkural Z, Vahaboglu H: Response to interferon-alpha in chronic hepatitis B patients with and without precore mutant strain and effects on HBsAg titers. Chemotherapy 2007; 53 (6): 402-406.
7. Furusyo N, Hayashi J, Kanamoto-Tanaka Y, et al. Liver damage in hemodialysis patients with hepatitis C virus viremia: a prospective 10-year study. Dig Dis Sci 2000; 45: 221-228.
8. Annicchiarico BE, Siciliano M: Pegylated interferonalpha 2b monotherapy for haemodialysis patients with chronic hepatitis C. Aliment Pharmacol Ther 2004; 20: 123-124.
9. Nakayama E, Akiba T, Marumo F, Sato C: Prognosis of anti-hepatitis C virus antibody-positive patients on regular hemodialysis therapy. J Am Soc Nephrol 2000; 11: 1896-1902.
10. Martin P, Mitra S, Farrington K, Martin NE, Modi MW: Pegylated (40 KDA) interferon alfa-2a (PegasysTM) is unaffected by renal impairment [Abstract]. Hepatology 2000; 32: 842.
11. Fabrizi F, Dulai G, Dixit V, bunnapradist S, Martin P: Meta-analysis: interferon for the treatment of chronic hepatitis C in dialysis patients. Aliment Pharmacol Ther 2003; 18: 1071-1081.
12. Russo MW, Goldsweig CD, Jacobson IM, Brown RS: Interferon monotherapy for dialysis patients with chronic hepatitis C: an analysis of the literature on efficacy and safety. Am J Gastroenterol 2003; 98: 1610-1615.
13. Bruchfeld A, Lindahl K, Reichard O, Carlsson T, Schvarcz R: Pegylated interferon and ribavirin treatment for hepatitis C in haemodialysis patients. J Viral Hepat 2006; 13: 316-321.
14. Rendina M, Schena A, Castellaneta NM, Losito F, Amoruso AC, Stallone G, Schena FP, Di Leo A, Francavilla A: The treatment of chronic hepatitis C with peginterferon alfa-2a (40 kDa) plus ribavirin in haemodialysed patients awaiting renal transplant. J Hepatol 2007; 46: 768-774.
15. Espinosa M, Arenas MD, Aumente MD, Barril G, Buades JM, Aviles B, Carretero D, Alvarez-Lara MA, Carnicer F, Martin-Malo A, Aljama P: Anemia associated with pegylated interferon-alpha2a and alpha2b therapy in hemodialysis patients. Clin Nephrol 2007; 67: 366-373.
16. Dor-Mohammadi T, Daryani NE, Bashashati M, Hashtrudi AA, Haghpanah B, Sayyah AR, Shakiba M: Relationship between serum alanine aminotransferase levels and liver histology in chronic hepatitis C-infected patients. Indian J Gastroenterol 2005; 24: 49-51.
17. Sporea I, Popescu A, Şirli R, Golea O, Totolici C, Da?nila? M, Vernic C: Pegylated-interferon alpha 2a treatment for chronic hepatitis C in patients on chronic haemodialysis. World J Gastroenterol 2006; 12: 4191-4194.